Solid form selection of zwitterionic 5-HT4 receptor agonist

International Journal of Pharmaceutics

Volumn 350, Issue 1-2, 2008, Pages 35-42

  Kojima, Takashi ^a   Sugano, Kiyohiko ^a   Onoue, Satomi ^a   Murase, Noriaki ^a   Sato, Morimichi ^a   Kawabata, Yohei ^a   Mano, Takashi ^a  

^a PFIZER INC   (United States)

Author keywords

Hydrate; Physical stability; Polymorph; Raman spectroscopy; Salt screening; Solid form selection

Indexed keywords

4 [[4 [[[(3 ISOPROPYL 2 OXO 2,3 DIHYDRO 1H BENZIMIDOZOL 1 YL)CARBONYL]AMINO]METHYL]PIPERIDIN 1 YL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOXYLIC ACID; AMPHOLYTE; SEROTONIN 4 AGONIST; UNCLASSIFIED DRUG;

ARTICLE; ATMOSPHERIC MOISTURE; DRUG MANUFACTURE; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HYDRATION; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAMAN SPECTROMETRY; SOLID STATE;

CALORIMETRY, DIFFERENTIAL SCANNING; DRUG STABILITY; HUMIDITY; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN AGONISTS; X-RAY DIFFRACTION;

EID: 38349135357     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.08.026     Document Type: Article

References (25)

1. Badawy S.I. Effect of salt form on chemical stability of an ester prodrug of a glycoprotein IIb/IIIa receptor antagonist in solid dosage forms. Int. J. Pharm. 223 (2001) 81-87
2. Bastin R.J., Bowker M.J., and Slater B.J. Salt selection and optimization procedures for pharmaceutical new chemical entities. Org. Process Res. Dev. 4 (2000) 427-435
3. Bergren M.S., Chao R.S., Meulman P.A., Sarver R.W., Lyster M.A., Havens J.L., and Hawley M. Solid phases of delavirdine mesylate. J. Pharm. Sci. 85 (1996) 834-841
4. Byrn S.R., Xu W., and Newman A.W. Chemical reactivity in solid-state pharmaceuticals: formulation implications. Adv. Drug Deliv. Rev. 48 (2001) 115-136
5. Engel G.L., Farid N.A., Faul M.M., Richardson L.A., and Winneroski L.L. Salt form selection and characterization of LY333531 mesylate monohydrate. Int. J. Pharm. 198 (2000) 239-247
6. Gandhi R.B., Bogardus J.B., Bugay D.E., Perrone R.K., and Kaplan M.A. Pharmaceutical relationships of three solid state forms of stavudine. Int. J. Pharm. 201 (2000) 221-237
7. Glass B.D., Novák C., and Brown M.E. The thermal and photostability of solid pharmaceuticals. J. Therm. Anal. Calorim. 77 (2004) 1013-1036
8. Gould P.L. Salt selection for basic drugs. Int. J. Pharm. 33 (1986) 201-217
9. Knapman K. Polymorphic predictions. Modern Drug Discovery vol. 3 (2000), American Chemical Society pp. 53-54, 57
10. Kojima T., Onoue S., Murase N., Katoh F., Mano T., and Matsuda Y. Crystalline form information from multi-well plate salt screening by use of Raman microscopy. Pharm. Res. 23 (2006) 806-812
11. Kojima T., Kato F., Teraoka R., Matsuda Y., Kitagawa S., and Tsuhako M. Physicochemical characterization of tamoxifen citrate pseudopolymorphs, ethanolate and methanolate. Chem. Pharm. Bull. 55 (2007) 407-411
12. Kojima T., Onoue S., Katoh F., Teraoka R., Matsuda Y., Kitagawa S., and Tsuhako M. Effect of spectroscopic properties on photostability of tamoxifen citrate polymorphs. Int. J. Pharm. 336 (2007) 346-351
13. Kushida I., and Ashizawa K. Solid state characterization of E2101, a novel antispastic drug. J. Pharm. Sci. 91 (2002) 2193-2202
14. Miller J.M., Collman B.M., Greene L.R., Grant D.J., and Blackburn A.C. Identifying the stable polymorph early in the drug discovery-development process. Pharm. Dev. Technol. 10 (2005) 291-297
15. Morissette S.L., Soukasene S., Levinson D., Cima M.J., and Almarsson O. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization. Proc. Natl. Acad. Sci. USA 100 (2003) 2180-2184
16. Morissette S.L., Almarsson O., Peterson M.L., Remenar J.F., Read M.J., Lemmo A.V., Ellis S., Cima M.J., and Gardner C.R. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv. Drug Deliv. Rev. 56 (2004) 275-300
17. Morris K.R., Fakes M.G., Thakur A.B., Newman A.W., and Singh A.K. An integrated approach to the selection of optimal salt form for a new drug candidate. Int. J. Pharm. 105 (1994) 209-217
18. Sacchetti M. Determining the relative physical stability of anhydrous and hydrous crystal forms of GW2016. Int. J. Pharm. 273 (2004) 195-202
19. Stahl P.H., and Wermuth C.G. Monographs on Acids and Bases. In: Stahl P.H., and Wermuth C.G. (Eds). Handbook of Pharmaceutical Salts: Properties, Selection, and Use (2002), VHCA Verlag Helvetica Chimica Acta, WILEY-VCH, Zürich (Switzerland), Weinheim (Federal Republic of Germany). 3-906390-26-8 266-327
20. Stahl, P.H., Nakano, M., 2002b. Pharmaceutical Aspects of the Drug Salt Form. In: Stahl, P.H., Wermuth, C.G., Eds.), Handbook of Pharmaceutical Salts: Properties, Selection, and Use, pp. 83-116.
21. Ticehurst M.D., Storey R.A., and Watt C. Application of slurry bridging experiments at controlled water activities to predict the solid-state conversion between anhydrous and hydrated forms using theophylline as model drug. Int. J. Pharm. 247 (2002) 1-10
22. Tong W.Q., and Whitesell G. In situ salt screening-a useful technique for discovery support and preformulation studies. Pharm. Dev. Technol. 3 (1998) 215-223
23. Trask A.V., Motherwell W.D., and Jones W. Pharmaceutical cocrystallization: engineering a remedy for caffeine hydration. Cryst. Growth Des. 5 (2005) 1013-1021
24. Vishweshwar P., McMahon J.A., Bis J.A., and Zaworotko M.J. Pharmaceutical co-crystals. J. Pharm. Sci. 95 (2006) 499-516
25. Zhu H., Yuen C., and Grant D.J.W. Influence of water activity in organic solvent + water mixtures on the nature of the crystallizing drug phase. 1. Theophylline. Int. J. Pharm. 135 (1996) 151-160